DUBLIN – Shares in Adocia SA gained 27 percent Thursday on news of a diabetes deal in China with Tonghua Dongbao Pharmaceutical Co. Ltd., under which it will pocket $50 million up front with up to $85 million more to come in potential development milestones, as well as double-digit sales royalties. The agreement covers Biochaperone Combo, its fixed-ratio combination of basal insulin (insulin glargine) and prandial insulin (insulin lispro), as well as its fast-acting insulin formulation Biochaperone Lispro, in China and several other countries.